We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




Drug Development Acquisition Focuses on Treatment for Movement Disorders

By LabMedica International staff writers
Posted on 12 Apr 2015
Print article
The purchase of a biomedical company that develops drugs for treatment of hyperkinetic movement disorders by one of the world's largest producers of generic drugs is expected to strengthen the generics manufacturer's position in the market for central nervous system condition treatments.

One of the world's largest producers of generic medicines, Teva Pharmaceutical Industries Ltd. (Jerusalem, Israel), is reportedly buying the drug development company Auspex Pharmaceuticals (La Jolla, CA, USA) for about 3.2 billion USD.

Auspex does not yet have a product on the market, but they plan to register their lead product SD-809 (Austedo) with the [US] Food and Drug Administration (FDA) later this year. Last December, Auspex reported positive results from a Phase III clinical trial evaluating SD-809 in chorea associated with Huntington's disease. In that randomized, double-blind, placebo-controlled, parallel-group trial, patients with Huntington’s disease (n=90) received SD-809 or placebo and monitored for 13 weeks. The primary endpoint was the change from baseline to maintenance therapy in the Total Maximal Chorea (TMC) score of the Unified Huntington's Disease Rating Scale (UHDRS). Numerous pre-specified secondary endpoints were also tested [treatment success based on patient global impression of change (PGIC) and clinical global impression of change (CGIC), quality of life and balance.]

At the end of the study, patients taking SD-809 achieved a meaningful improvement of 2.5 points on the TMC score from baseline to maintenance therapy compared to placebo. The secondary endpoints were also very impressive with significant differences in PGIC and CGIC scores. Equally important, the drug was well tolerated and safe with no differences being reported with adverse events between patients given SD-809 and those given placebo.

"The acquisition of Auspex is a significant step in strengthening Teva's leadership position in central nervous system (disorders) and advances us into underserved movement disorder markets," said Erez Vigodman, president and CEO of Teva.

Teva anticipates initiating marketing of Austedo in 2016.

Related Links:

Teva Pharmaceutical Industries Ltd.
Auspex Pharmaceuticals


New
Gold Member
ANA & ENA Screening Assays
ANA and ENA Assays
Unit-Dose Packaging solution
HLX
New
Monkeypox Test
Monkeypox Virus Rapid Antibody Test
New
Automated Nucleic Acid Extractor
eLab

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: The bowel cancer breakthrough could result in better treatment outcomes (Photo courtesy of 123RF)

New RNA Molecules Can Help Predict Bowel Cancer Return Recurrence

Colorectal cancer accounts for 10% of all cancer-related deaths worldwide and was ranked as the second most common cause of cancer death in the United States in 2022. Currently, clinicians face diagnostic... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image

AI-Based Method Shows Promise for Pathological Diagnosis of Hereditary Kidney Diseases

Alport syndrome is a hereditary kidney disorder characterized by kidney dysfunction, sensorineural hearing loss, and ocular abnormalities. Early in the disease, patients experience hematuria, which is... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.